dc.contributor | Universidade de São Paulo (USP) | |
dc.contributor | Universidade Estadual Paulista (Unesp) | |
dc.date.accessioned | 2014-05-27T11:23:58Z | |
dc.date.available | 2014-05-27T11:23:58Z | |
dc.date.created | 2014-05-27T11:23:58Z | |
dc.date.issued | 2009-09-15 | |
dc.identifier | Journal of Immune Based Therapies and Vaccines, v. 7, p. 4-. | |
dc.identifier | 1476-8518 | |
dc.identifier | http://hdl.handle.net/11449/71151 | |
dc.identifier | 10.1186/1476-8518-7-4 | |
dc.identifier | 2-s2.0-70449432883 | |
dc.identifier | 2-s2.0-70449432883.pdf | |
dc.description.abstract | Background: Our group previously demonstrated that a DNA plasmid encoding the mycobacterial 65-kDa heat shock protein (DNA-HSP65) displayed prophylactic and therapeutic effect in a mice model for tuberculosis. This protection was attributed to induction of a strong cellular immunity against HSP65. As specific immunity to HSP60 family has been detected in arthritis, multiple sclerosis and diabetes, the vaccination procedure with DNA-HSP65 could induce a cross-reactive immune response that could trigger or worsen these autoimmune diseases. Methods: In this investigation was evaluated the effect of a previous vaccination with DNA-HSP65 on diabetes development induced by Streptozotocin (STZ). C57BL/6 mice received three vaccine doses or the corresponding empty vector and were then injected with multiple low doses of STZ. Results: DNA-HSP65 vaccination protected mice from STZ induced insulitis and this was associated with higher production of IL-10 in spleen and also in the islets. This protective effect was also concomitant with the appearance of a regulatory cell population in the spleen and a decreased infiltration of the islets by T CD8+ lymphocytes. The vector (DNAv) also determined immunomodulation but its protective effect against insulitis was very discrete. Conclusion: The data presented in this study encourages a further investigation in the regulatory potential of the DNA-HSP65 construct. Our findings have important implications for the development of new immune therapy strategies to combat autoimmune diseases. © 2009 Santos et al; licensee BioMed Central Ltd. | |
dc.language | eng | |
dc.relation | Journal of Immune Based Therapies and Vaccines | |
dc.rights | Acesso aberto | |
dc.source | Scopus | |
dc.subject | CD103 antigen | |
dc.subject | CD4 antigen | |
dc.subject | CD8 antigen | |
dc.subject | cytotoxic T lymphocyte antigen 4 | |
dc.subject | DNA vaccine | |
dc.subject | heat shock protein 65 | |
dc.subject | interleukin 10 | |
dc.subject | interleukin 2 receptor alpha | |
dc.subject | monoclonal antibody | |
dc.subject | streptozocin | |
dc.subject | tumor necrosis factor alpha | |
dc.subject | animal cell | |
dc.subject | animal experiment | |
dc.subject | animal model | |
dc.subject | animal tissue | |
dc.subject | autoimmunity | |
dc.subject | CD8+ T lymphocyte | |
dc.subject | controlled study | |
dc.subject | cytokine production | |
dc.subject | DNA vector | |
dc.subject | immunomodulation | |
dc.subject | immunotherapy | |
dc.subject | insulitis | |
dc.subject | lymphocyte subpopulation | |
dc.subject | lymphocytic infiltration | |
dc.subject | male | |
dc.subject | mouse | |
dc.subject | Mycobacterium | |
dc.subject | nonhuman | |
dc.subject | pancreas islet | |
dc.subject | regulatory T lymphocyte | |
dc.subject | spleen | |
dc.subject | streptozocin diabetes | |
dc.subject | treatment outcome | |
dc.title | DNA vaccine containing the mycobacterial hsp65 gene prevented insulitis in MLD-STZ diabetes | |
dc.type | Artículos de revistas | |